Clinical Trial Update: Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating Basiliximab to prevent acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation in patients with b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta Thalassemia Major
• Graft-versus-host Disease

Drugs mentioned

• Simulect (Basiliximab)

Snippet

Sponsor: Zhongming Zhang | Conditions: Beta-Thalassemia Major, Graft-versus-host Disease (GVHD) | Phase 4 | Status: COMPLETED